COVID-19 spike variants antigen Recombinant 2019-nCoV(SARS-CoV-2) (UK variant B.1.1.7 lineage) Spike Protein RBD-N501Y mutant (SRBD-N501Y,C-HisTag)

COVID-19 recombinant SARS-CoV2 (2019 nCoV coronavirus)antigen:
Recombinant 2019-nCoV(SARS-CoV-2) (UK variant B.1.1.7 lineage)
Spike Protein RBD-N501Y mutant (SRBD-N501Y,C-HisTag)
Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-21 vaccines and therapeutic antibodies.
Validated in functional ELISA, other immunoassays, The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection. The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell entry and is the dominant target of the immune system. Most mutations and deletions of SARS-CoV-2 occur in the coronavirus spike protein. Spike position N501, one of the key contact residues in the receptor-binding domain (RBD), and experimental data suggest mutation N501Y can increase ACE2 receptor affinity (Starr et al. 2020). N501Y has also been associated with increased infectivity and virulence in a mouse model (Gu et al. 2020).
Recently a novel SARS-COV-2 (2019nCOV) lineage, the B.1.1.7 lineage, with serials of site mutation, shows stronger infection ability in the UK. In SARS-COV-2 B.1.1.7 lineage, most mutations and deletions occur in the coronavirus spike protein. These mutantions also include SARS-CoV-2 spike- mutation. N501Y mutation is also found in the South Africa 501Y.V2 lineage.

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) Spike-N501Y mutation
Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) spike-N501Y mutation, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies.
GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) spike-N501Y mutation
GeneMedi designed a mammalian expression codon-optimized spike mutation/deletion variant vector for COVID-19 SARS-COV-2 (2019nCOV) spike-N501Y mutation
The mutations and deletions information of GeneMedi’s codon-optimized Spike vector for SARS-COV-2 B.1.1.7 lineage in UK COVID-19 pandemic recently:

21765-21770 deletion HV 69-70 deletion Spike-S1 Subunit
21991-21993 deletion Y144 deletion Spike-S1 Subunit
A23063T N501Y Spike-S1 Subunit-RBD
C23271A A570D Spike-S1 Subunit
C23604A P681H Spike-S1 Subunit
C23709T T716I Spike-S2 Subunit
T24506G S982A Spike-S2 Subunit
G24914C D1118H Spike-S2 Subunit